Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019. AtriCure will host a conference cal...
Thinly traded AtriCure ( ATRC +6.8% ) is up on average volume, a modest 200K shares, as JPMorgan steps in to defend the stock after yesterday's 10% selloff in apparent reaction to a bearish report from Culper Research . More news on: AtriCure, Inc., Healthcare stocks news, S...
Clinical evidence demonstrates that AtriClip ® devices exclude and electrically isolate the left atrial appendage AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Morgan Stanley 17 th Annual Global Healthcare Conference in New York C...
Now China claims US broke the negotiation agreement The market futures plunge after China threatens retaliation. Then China backtracks, and the market goes back up. China claims the US broke the agreement; we say China did. Am I the only one who is bored with the whole nonsense? All I can ...
Quick Take AtriCure ( ATRC ) announced it has agreed to acquire SentreHEART for $40 million plus additional contingent consideration of up to $260 million. SentreHEART is developing percutaneous left atrial appendage management solutions. With the deal, ATRC is gaining promising techno...
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial a...
Investors appear to lack enthusiasm for AtriCure's ( ATRC -8.1% ) planned takeover of SentreHEART, the developer of a suture delivery device called LARIAT for left atrial appendage closure. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Stocks on t...
AtriCure (NASDAQ: ATRC ) has agreed to acquire privately held SentreHEART , a developer of percutaneous left atrial appendage management solutions. More news on: AtriCure, Inc., Healthcare stocks news, Merger & acquisition news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...